Network pharmacology study of Seleromitrion diffusa (Willd). R. J. Wang and Scutellaria barbata D. Don in the treatment of chronic atrophic gastritis

Abstract

ObjectiveThe study aimed to investigate Scutellaria barbata D. Don and Seleromitrion diffusa (Willd). R. J. Wang (HDSB) in the treatment of chronic atrophic gastritis (CAG) by using network pharmacology and literature research. MethodsTCMSP, Uniprot, Drug Bank, OMIM, and GeneCards were used to obtain the active components, targets of Scutellaria barbata D. Don and Seleromitrion diffusa (Willd). R. J. Wang and the disease targets of CAG. Cytoscape 3.9.1 was used to construct a drug network. STRING platform was used to analyze the PPI network, and Metascape was used for functional enrichment analysis and KEGG pathway enrichment analysis. ResultsThe study found a total of 34 active compounds of HDSB, 153 predicted targets, 970 disease targets, and 46 intersection targets of CAG. And identified a total of 27 prescriptions or proprietary Chinese medicines containing Scutellaria barbata D. Don and Seleromitrion diffusa (Willd). R. J. Wang through literature research and database search, that consists in a 1:1, 1:2, or 2:1 ratio, with a dose range of 15 ​g–300 ​g. ConclusionThe study suggests that Scutellaria barbata D. Don and Seleromitrion diffusa (Willd). R. J. Wang may exert therapeutic effects on chronic atrophic gastritis by acting on JNK, PI3K-Akt, HIF-1, cancer-related and others.